Cargando…

A multi-criteria decision analysis (MCDA) tool for purchasing off-patent oncology medicines in Egypt

BACKGROUND: Multi- criteria decision analysis (MCDA) can assist policymakers in objectively choosing between alternative therapeutic options based on multiple value attributes. Our aim was to create an MCDA tool for the national tenders of off-patent oncology medicines in Egypt. METHODS: An initial...

Descripción completa

Detalles Bibliográficos
Autores principales: Elezbawy, Baher, Fasseeh, Ahmad Nader, Sedrak, Amal, Eldessouki, Randa, Gamal, Mary, Eldebeiky, Mariam, Amer, Hanaa, Akeel, Shimaa, Morsy, Ahmad, Amin, Amira, Shafik, Amr, Abaza, Sherif, Kaló, Zoltán
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886839/
https://www.ncbi.nlm.nih.gov/pubmed/35232487
http://dx.doi.org/10.1186/s40545-022-00414-2
_version_ 1784660766435049472
author Elezbawy, Baher
Fasseeh, Ahmad Nader
Sedrak, Amal
Eldessouki, Randa
Gamal, Mary
Eldebeiky, Mariam
Amer, Hanaa
Akeel, Shimaa
Morsy, Ahmad
Amin, Amira
Shafik, Amr
Abaza, Sherif
Kaló, Zoltán
author_facet Elezbawy, Baher
Fasseeh, Ahmad Nader
Sedrak, Amal
Eldessouki, Randa
Gamal, Mary
Eldebeiky, Mariam
Amer, Hanaa
Akeel, Shimaa
Morsy, Ahmad
Amin, Amira
Shafik, Amr
Abaza, Sherif
Kaló, Zoltán
author_sort Elezbawy, Baher
collection PubMed
description BACKGROUND: Multi- criteria decision analysis (MCDA) can assist policymakers in objectively choosing between alternative therapeutic options based on multiple value attributes. Our aim was to create an MCDA tool for the national tenders of off-patent oncology medicines in Egypt. METHODS: An initial list of criteria was developed through a literature review complemented by local expert interviews. Price or cost-related criteria were excluded to abide by the national regulations of the tender process. Next, a workshop hosting diversified stakeholders representing different governmental bodies was held. Anonymous voting was used to rank and weigh the criteria as well as assigning scores. Price was added as a separate step to identify best option based on price per point. The tool was then tested on a national tender sample of off-patent oncology medicines to assess its performance, and it was readjusted accordingly in a second workshop. RESULTS: Seven non-price criteria were selected, including use in reference countries (23.49% weight), equivalence with the reference product (18.79%), manufacturing quality (15.53%), provision of pharmacovigilance services (12.94%), supply reliability (10.78%), previous use in local settings (9.8%) and macroeconomic benefit (8.67%). A medicine receives a score ranging from 0 to 100% of each criterion’s weight. The aggregated score is calculated on a hundred-point scale. Based on participants’ consensus, an overall score of 65 was set as a cut-off for passing the technical eligibility phase of the tendering process. Any product receiving a lower score would be disqualified from the tender. For qualified products, the lower price per point represents preferential option for the national tender. CONCLUSIONS: The created MCDA tool is capable of objectively comparing similar off-patent oncology medicines by considering multiple value attributes and providing reliable scoring functions for each.
format Online
Article
Text
id pubmed-8886839
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88868392022-03-17 A multi-criteria decision analysis (MCDA) tool for purchasing off-patent oncology medicines in Egypt Elezbawy, Baher Fasseeh, Ahmad Nader Sedrak, Amal Eldessouki, Randa Gamal, Mary Eldebeiky, Mariam Amer, Hanaa Akeel, Shimaa Morsy, Ahmad Amin, Amira Shafik, Amr Abaza, Sherif Kaló, Zoltán J Pharm Policy Pract Research BACKGROUND: Multi- criteria decision analysis (MCDA) can assist policymakers in objectively choosing between alternative therapeutic options based on multiple value attributes. Our aim was to create an MCDA tool for the national tenders of off-patent oncology medicines in Egypt. METHODS: An initial list of criteria was developed through a literature review complemented by local expert interviews. Price or cost-related criteria were excluded to abide by the national regulations of the tender process. Next, a workshop hosting diversified stakeholders representing different governmental bodies was held. Anonymous voting was used to rank and weigh the criteria as well as assigning scores. Price was added as a separate step to identify best option based on price per point. The tool was then tested on a national tender sample of off-patent oncology medicines to assess its performance, and it was readjusted accordingly in a second workshop. RESULTS: Seven non-price criteria were selected, including use in reference countries (23.49% weight), equivalence with the reference product (18.79%), manufacturing quality (15.53%), provision of pharmacovigilance services (12.94%), supply reliability (10.78%), previous use in local settings (9.8%) and macroeconomic benefit (8.67%). A medicine receives a score ranging from 0 to 100% of each criterion’s weight. The aggregated score is calculated on a hundred-point scale. Based on participants’ consensus, an overall score of 65 was set as a cut-off for passing the technical eligibility phase of the tendering process. Any product receiving a lower score would be disqualified from the tender. For qualified products, the lower price per point represents preferential option for the national tender. CONCLUSIONS: The created MCDA tool is capable of objectively comparing similar off-patent oncology medicines by considering multiple value attributes and providing reliable scoring functions for each. BioMed Central 2022-03-01 /pmc/articles/PMC8886839/ /pubmed/35232487 http://dx.doi.org/10.1186/s40545-022-00414-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Elezbawy, Baher
Fasseeh, Ahmad Nader
Sedrak, Amal
Eldessouki, Randa
Gamal, Mary
Eldebeiky, Mariam
Amer, Hanaa
Akeel, Shimaa
Morsy, Ahmad
Amin, Amira
Shafik, Amr
Abaza, Sherif
Kaló, Zoltán
A multi-criteria decision analysis (MCDA) tool for purchasing off-patent oncology medicines in Egypt
title A multi-criteria decision analysis (MCDA) tool for purchasing off-patent oncology medicines in Egypt
title_full A multi-criteria decision analysis (MCDA) tool for purchasing off-patent oncology medicines in Egypt
title_fullStr A multi-criteria decision analysis (MCDA) tool for purchasing off-patent oncology medicines in Egypt
title_full_unstemmed A multi-criteria decision analysis (MCDA) tool for purchasing off-patent oncology medicines in Egypt
title_short A multi-criteria decision analysis (MCDA) tool for purchasing off-patent oncology medicines in Egypt
title_sort multi-criteria decision analysis (mcda) tool for purchasing off-patent oncology medicines in egypt
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886839/
https://www.ncbi.nlm.nih.gov/pubmed/35232487
http://dx.doi.org/10.1186/s40545-022-00414-2
work_keys_str_mv AT elezbawybaher amulticriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt
AT fasseehahmadnader amulticriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt
AT sedrakamal amulticriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt
AT eldessoukiranda amulticriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt
AT gamalmary amulticriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt
AT eldebeikymariam amulticriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt
AT amerhanaa amulticriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt
AT akeelshimaa amulticriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt
AT morsyahmad amulticriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt
AT aminamira amulticriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt
AT shafikamr amulticriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt
AT abazasherif amulticriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt
AT kalozoltan amulticriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt
AT elezbawybaher multicriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt
AT fasseehahmadnader multicriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt
AT sedrakamal multicriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt
AT eldessoukiranda multicriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt
AT gamalmary multicriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt
AT eldebeikymariam multicriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt
AT amerhanaa multicriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt
AT akeelshimaa multicriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt
AT morsyahmad multicriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt
AT aminamira multicriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt
AT shafikamr multicriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt
AT abazasherif multicriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt
AT kalozoltan multicriteriadecisionanalysismcdatoolforpurchasingoffpatentoncologymedicinesinegypt